Department of Rheumatology and NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Department of Clinical and Experimental Medicine, Regional Referral Centre for Rare Lung Diseases, A.O.U. "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy.
Inflamm Res. 2020 Aug;69(8):757-763. doi: 10.1007/s00011-020-01366-6. Epub 2020 May 28.
The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.
由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年新型冠状病毒病（COVID-19）大流行正在严重考验世界各地的医疗保健系统和经济，被认为是本世纪的主要卫生紧急事件。尽管在许多情况下疾病的病程似乎较轻，但相当一部分有症状的患者会出现肺炎，需要住院治疗，或进展为表现出呼吸并发症，需要重症监护治疗。目前正在测试针对 SARS-CoV2 相关肺炎的潜在干预措施，其中一些措施有希望，但截至今天，没有一种方法在治疗 COVID-19 方面表现出卓越的疗效。在本文中，我们讨论了免疫失调在 COVID-19 中的潜在作用的新观点和见解，以及与败血症全身炎症反应的相似之处，以及探索影响宿主免疫反应的新型治疗选择的理由。
